PALO ALTO, Calif., Feb. 8, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 14 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the presentation can be accessed for 30 days following the presentation.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.